MTA-Bound PRMT5 Inhibitors for Selective MTAP-Null Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PRMT5 inhibitors pose significant liabilities in normal tissues due to their non-specific inhibition, leading to side effects such as pan-cytopenia, infertility, and skeletal muscle loss, while MTAP null tumors benefit from PRMT5 inhibition due to elevated MTA levels, necessitating a strategy to selectively target PRMT5 in these tumors without affecting normal cells.
Innovation Solution
Development of novel PRMT5 inhibitors that preferentially target the MTA-bound state of PRMT5 in MTAP null tumor cells, utilizing specific small molecule compounds that exploit the metabolic vulnerability of PRMT5 in these cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 is inhibited using conventional inhibitors, then PRMT5 activity is blocked in tumor cells, but normal tissues are also affected causing severe side effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features (aromatic rings with electron-withdrawing groups, particular substitution patterns) that enable selective binding to PRMT5 in MTAP-null cells. The molecular structure is optimized to recognize and bind preferentially to the MTA-bound state of PRMT5, which is enriched in tumor cells but absent in normal tissues, thereby achieving localized therapeutic effect while sparing normal tissues.
Solution Approach 2:
The patent employs parameter changes by modifying key molecular parameters of the inhibitors including the introduction of specific functional groups (nitro, cyano, trifluoromethyl), adjustment of ring substitution patterns, and optimization of molecular weight and lipophilicity. These parameter modifications enhance the inhibitors' ability to selectively target the MTA-bound state of PRMT5 in tumor cells while maintaining adequate pharmacokinetic properties for therapeutic use.
2Productivity
If PRMT5 inhibition is applied broadly, then tumor cell growth is suppressed, but normal cellular functions are disrupted causing pan-cytopenia and other liabilities
Solution Approach 1:
The patent applies preliminary action by exploiting the pre-existing metabolic vulnerability in MTAP-null tumor cells. These cells already have elevated MTA levels due to loss of MTAP enzyme function. The inhibitors are designed to bind specifically to PRMT5 when it is in the MTA-bound state, which is already present in tumor cells before treatment. This preliminary metabolic alteration in tumor cells creates a selective target that normal cells lack, allowing selective tumor cell suppression without disrupting normal cellular functions.
3Adaptability or versatility
If non-specific PRMT5 inhibitors are used, then broad PRMT5 inhibition is achieved, but selectivity for MTAP null tumors is lost
Solution Approach 1:
The patent uses MTA as an intermediary that mediates the selective interaction between the inhibitors and PRMT5 in tumor cells. MTA naturally binds to PRMT5 in MTAP-null tumor cells, creating a stable MTA-PRMT5 complex. The inhibitors are designed to bind to this complex rather than to free PRMT5, effectively using MTA as a bridge or intermediary that enables selective recognition and binding. This intermediary mechanism provides high selectivity for tumors while maintaining effective PRMT5 inhibition in the tumor context.
Data Source
AI summary
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure: